Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 110

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Not recruiting

Study on Oral PHA-022121 for Preventing Angioedema Attacks in Patients with Hereditary Angioedema

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(S)-N-(1-Deutero-1-(3-Chloro-5-Fluoro-2-((2-Methyl-4-(1-Methyl-1H-1,2,4-Triazol-5-Yl)Quinolin-8-Yloxy)Methyl)Phenyl)Ethyl)-2-(Difluoromethoxy)Acetamide
  • Sponsor:Pharvaris Netherlands B.V.

Giant cell arteritis

Not recruiting

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Folic Acid
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Psoriatic arthropathy

Not recruiting

Study on Upadacitinib for Pain Management in Patients with Psoriatic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Universitaetsklinikum Erlangen AöR

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Obinutuzumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:F. Hoffmann-La Roche AG

HIV infection

Not recruiting

Study on Budigalimab and ABBV-382 for People with HIV on Stable Antiretroviral Therapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

HIV infection

Not recruiting

Study on HIV-1 Treatment for Patients New to Therapy: Comparing Doravirine/Islatravir with a Drug Combination

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative+1

Not recruiting

Study on the Long-term Safety of Vedolizumab for Children with Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Atopic keratoconjunctivitis

Not recruiting

Study on the Safety and Effectiveness of Isocyclosporin A Eye Drops for Adults with Atopic Keratoconjunctivitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fluorescein Sodium
  • Sponsor:Dompe' Farmaceutici S.p.A.

Immunoglobulin G4 related disease

Not recruiting

Study on the Effectiveness of Inebilizumab for Patients with IgG4-Related Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Neuromyelitis optica spectrum disorder

Not recruiting

Study on the Effectiveness and Safety of Ravulizumab for Children and Adolescents with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Type 1 diabetes mellitus

Not recruiting

Study on Insulin Lispro and Insulin Human for Managing Blood Sugar After Meals in Type 1 Diabetes Patients with Different Gastric Emptying Rates

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Human (Rdna)
  • Sponsor:Katholisches Klinikum Bochum gGmbH

Systemic mastocytosis

Not recruiting

Study of BLU-263 and Azacitidine for Patients with Advanced Systemic Mastocytosis and Other KIT Altered Blood Cancers

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Blueprint Medicines Corp.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.